Tuhura Biosciences Inc (HURA)

Feb 27, 2026, 7:30 AM EST - 16 days ago

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 24, 2026, 5:20 PM EST - 19 days ago

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

Feb 17, 2026, 7:45 AM EST - 26 days ago

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

Feb 12, 2026, 7:45 AM EST - 4 weeks ago

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 2, 2026, 7:45 AM EST - 5 weeks ago

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

Dec 15, 2025, 7:50 AM EST - 3 months ago

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

Dec 11, 2025, 7:30 AM EST - 3 months ago

TuHURA Biosciences Provides Corporate Update Following Recent Financing

Dec 9, 2025, 9:49 AM EST - 3 months ago

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

Dec 8, 2025, 7:50 AM EST - 3 months ago

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

Nov 14, 2025, 7:00 AM EST - 4 months ago

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 3, 2025, 9:01 AM EST - 4 months ago

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Aug 20, 2025, 8:00 AM EDT - 7 months ago

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 7 months ago

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 10, 2025, 4:00 AM EDT - 8 months ago

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Jul 1, 2025, 8:50 AM EDT - 9 months ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 8:50 AM EDT - 9 months ago

TuHURA Biosciences Completes Acquisition of Kineta

Jun 24, 2025, 8:00 AM EDT - 9 months ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

Jun 23, 2025, 5:00 PM EDT - 9 months ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Jun 9, 2025, 8:00 AM EDT - 9 months ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 3, 2025, 9:58 AM EDT - 10 months ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 2, 2025, 8:03 AM EDT - 10 months ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

May 15, 2025, 4:10 PM EDT - 10 months ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 10 months ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 5, 2025, 8:00 AM EDT - 11 months ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

Apr 28, 2025, 8:00 AM EDT - 11 months ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 7, 2025, 8:24 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 1, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Mar 11, 2025, 8:05 AM EDT - 1 year ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 10, 2025, 9:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 20, 2024, 10:18 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

Dec 12, 2024, 8:45 AM EST - 1 year ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Nov 25, 2024, 8:35 AM EST - 1 year ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Oct 23, 2024, 8:30 AM EDT - 1 year ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 22, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 17, 2024, 4:35 PM EDT - 1 year ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 16, 2024, 12:54 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 11:58 AM EDT - 1 year ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 9:25 AM EDT - 1 year ago

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Aug 19, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Jul 8, 2024, 6:30 AM EDT - 1 year ago

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Jul 1, 2024, 8:35 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones